Biogen (BIIB) Cash from Investing Activities Growth (3y) (2012 - 2026)
Biogen (BIIB) Cash from Investing Activities Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 33.51% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -51.98% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 21.19% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -43.40% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -77.58% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -39.19% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -177.73% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 27.70% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 83.15% |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn | -72.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -72.08% |
| Mar 31, 2026 | 39.65% |
| Dec 31, 2025 | -105.90% |
| Sep 30, 2025 | -26.43% |
| Jun 30, 2025 | -27.69% |
| Mar 31, 2025 | 58.21% |
| Dec 31, 2024 | 45.15% |
| Sep 30, 2024 | -71.63% |
| Jun 30, 2024 | 71.62% |
| Mar 31, 2024 | -0.67% |
| Dec 31, 2023 | -57.68% |
| Sep 30, 2023 | -221.56% |
| Jun 30, 2023 | 3.28% |
| Mar 31, 2023 | -60.72% |
| Dec 31, 2022 | -30.04% |
| Sep 30, 2022 | 87.29% |
| Jun 30, 2022 | 102.14% |
| Mar 31, 2022 | -67.67% |
| Dec 31, 2021 | 58.92% |
| Sep 30, 2021 | 27.74% |